Gene on Link, the U.S. subsidiary of Taiwan-based Kim Forest, has obtained both CLIA and CAP high-level testing certifications in the United States, making Kim Forest the only lab with top-tier certifications in both Taiwan and the U.S. With the recent passage of the U.S. “Biosecurity Act,” Kim Forest is positioned to replace testing capabilities previously filled by Chinese manufacturers, thereby expanding its market presence. Kim Forest offers healthcare providers and labs a comprehensive suite of services, including equipment setup, supply of consumables, data analysis, and clinical consulting. Additionally, it can meet client needs by managing cross-border testing services between the U.S. and Taiwan.
Kim Forest’s product line now includes testing for 16 types of cancer, positioning it as Taiwan’s biotech leader with the most comprehensive range of cancer genetic tests. The company continues to expand its precision testing offerings, covering all types of solid tumors. For example, acute myeloid leukemia (AML) is known for its rapid progression, with a five-year survival rate of just 7%, making it crucial for doctors to find effective treatment strategies quickly. Kim Forest has recently expanded its certified testing services to include high-complexity genetic tests like hematologic malignancies, comprehensive tumor tissue drug testing (TSO500 tissue), and broad-based liquid biopsy testing for circulating tumor DNA (TSO500 ctDNA), thereby providing hospitals with enhanced therapeutic guidance.
Kim Forest highlighted its collaboration with Illumina, the leading brand in next-generation sequencing (NGS), to offer the cutting-edge TSO500 liquid biopsy monitoring service. TSO500 is widely used by pharmaceutical companies and hospitals worldwide. With this certification, Kim Forest can support both domestic and international clinical trials. As tumor samples can be challenging to obtain, this non-invasive liquid biopsy method detects circulating tumor DNA (ctDNA) in the blood, enabling early tumor detection and providing a comprehensive view of genetic mutations across multiple tumor sites, offering patients a critical lifeline. For hematologic cancers, especially AML, Jin Wanlin has developed a specialized blood cancer test kit that delivers genetic mutation results within 10 working days, aiding doctors and patients in timely diagnosis and personalized treatment planning.
Recent Comments